Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) remains negative

Q1 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.

Context

  • Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$1.76M— YoY
Year agoMar 2025
$0— since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
1.76M USD
Year-over-year change
—

Deferred Revenue (Non-current) vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's Mar 2026 deferred revenue (non-current) of $0 is the 3rd highest of the 10 companies compared; the peer median is $0.
  • Deferred revenue (non-current) amounts to 0.0% of total assets for ETON, versus a peer median of 0.0%.
ETON Competitors Peer median
Deferred Revenue (Non-current) for ETON and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$48.76M -54.8%-31.6%1.7%
FENCFennec Pharmaceuticals Inc.Mar 2026$24.56M ——34.2%
ETONEton Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
TVTXTravere Therapeutics, Inc.Sep 2026$0 ——0.0%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$0 ——0.0%
PHARPharming Group N.V.Mar 2026$0 ——0.0%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ZVRAZevra Therapeutics, Inc.Mar 2026$0 ——0.0%
DMACDiaMedica Therapeutics Inc.Mar 2026$0 ——0.0%
LRMRLarimar Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ETON) $0-54.8%-31.6%0.0%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents14.41M16.31M21.39M14.94M25.94M
Short-term Investments00000
Net Receivables5.47M1.85M3.41M5.36M11.76M
Inventory550K557K911K15.23M15.42M
Other Current Assets01.29M05.49M7.46M
Total Current Assets23.6M20M26.84M41.02M60.58M
Property, Plant & Equipment (Net)219K260K150K209K636K
Goodwill00000
Intangible Assets3.62M4.75M4.74M34.88M30.88M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets21K12K12K12K19K
Total Non-current Assets3.86M5.03M4.9M35.1M31.53M
Total Assets27.47M25.03M31.74M76.12M92.11M
Account Payables1.77M1.77M1.85M4.17M10.98M
Short-term Debt1.42M1.03M5.38M76K8.79M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00015.66M0
Total Current Liabilities4.56M6.46M16.24M19.95M38.49M
Long-term Debt5.26M5.38M029.81M21.77M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.76M
Other Non-current Liabilities0001.83M3.48M
Total Non-current Liabilities5.28M5.49M22K31.75M27.47M
Total Liabilities9.84M11.95M16.26M51.7M65.96M
Common Stock25K25K26K27K27K
Retained Earnings(94.11M)(103.13M)(104.07M)(107.89M)(112.49M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity17.63M13.08M15.48M24.43M26.15M
Total Debt6.7M6.52M5.4M29.99M31.02M
Net Debt(7.71M)(9.78M)(15.99M)15.06M5.08M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.